James Brugarolas, MD, PhD, discusses updated survival data in patients with metastatic renal cell carcinoma.
James Brugarolas, MD, PhD, director of the Kidney Cancer Program, professor of Internal Medicine, and the Sherry Wigley Crow Cancer Research Endowed Chair at the University of Texas Southwestern Medical Center, discusses updated survival data in patients with metastatic renal cell carcinoma (RCC).
According to Brugarolas, the prognosis of patients with metastatic RCC has significantly improved. This improvement has come in to 2 waves, the first with targeted therapies and the second with combination immunotherapy (IO) and tyrosine kinase inhibitors (TKIs). According to Brugarolas, the median survival of patients with metastatic RCC could be approaching 5 years.
0:08 | Well, so the prognosis of patients with metastatic RCC has improved significantly. The first improvement was with targeted therapies. Now the second wave was immunotherapies. And now with the combination of IO/TKI therapies. So, the most recent data we have is that patients nowadays, their median survival could be approaching five years, which is quite significantly improved compared to prior.
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Deciding Factors for Front-Line Therapy in Metastatic RCC
April 17th 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More